Acrivon acquires JAK1 inhibitor ACR-525 from Aqilion, enters immunology
Acrivon Therapeutics paid cash for a Phase 2-ready oral JAK1 inhibitor and a preclinical PKCθ program, establishing immunology and inflammation as a new pillar alongside oncology.
SEC filing